Showing 2623 results
- https://www.novartis.com/news/media-releases/novartis-data-eha-show-increased-pfs-benefit-farydak-new-subgroup-patients-previously-treated-multiple-myelomaPanobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an…
- https://www.novartis.com/news/media-releases/novartis-drug-arzerra-improved-median-progression-free-survival-54-patients-relapsed-chronic-lymphocytic-leukemiaArzerra significantly improved PFS when added to fludarabine + cyclophosphamide (median 28.9 mos vs 18.8 mos) after initial treatment stopped working Patients receiving Arzerra plus…
- https://www.novartis.com/news/media-releases/novartis-reports-new-analysis-showing-xolair-improving-quality-life-78-chronic-spontaneous-urticaria-patientsNew analysis from pivotal Phase III studies show Xolair® (omalizumab) significantly improved quality of life scores for Chronic Spontaneous Urticaria (CSU) patients compared to placebo[1],[2]…
- https://www.novartis.com/news/media-releases/novartis-gains-fda-approval-promacta-providing-new-option-children-ages-6-and-older-chronic-itp-rare-blood-disorderPromacta® (eltrombopag) significantly increased and sustained platelet counts in two studies, including the largest Phase III clinical trial in this patient population Characterized by a low…
- https://www.novartis.com/news/media-releases/novartis-presents-new-data-wcd-demonstrating-significant-efficacy-cosentyx-patients-psoriasis-nails-palms-and-solesCosentyx (secukinumab) met the primary endpoints of superiority compared to placebo in patients with difficult-to-treat psoriasis of the nails, palms and soles[1],[2] One third of patients…
- https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-farydak-first-its-class-anticancer-agents-approved-patients-multiple-myelomaFarydak (panobinostat) combination is approved in the EU for patients with multiple myeloma who received >=2 prior regimens including bortezomib and IMiD[1] In clinical trials, Farydak…
- https://www.novartis.com/news/media-releases/sandoz-launches-zarxiotm-filgrastim-sndz-first-biosimilar-united-statesLaunch follows March 6, 2015 FDA approval Sandoz One SourceTM offers patient support services The digital press release with multimedia content can be accessed here: Holzkirchen,…
- https://www.novartis.com/news/media-releases/novartis-receives-eu-approval-new-revolade-use-first-class-therapy-patients-severe-aplastic-anemiaRevolade is the first approved therapy in the EU for patients with severe aplastic anemia (SAA) who have not responded to other treatments Patients living with SAA, a rare blood disorder,…
- https://www.novartis.com/news/media-releases/novartis-announces-global-partnership-amgen-develop-and-commercialize-pioneering-neuroscience-treatmentsThe companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule Novartis and Amgen also plan…
- https://www.novartis.com/news/media-releases/novartis-setzt-sich-weiter-fur-die-endgultige-ausrottung-von-lepra-einDie Vereinbarung für die kommenden fünf Jahre umfasst Spenden von Behandlungseinheiten im Wert von mehr als USD 40 Millionen, mit denen rund 1,3 Millionen Patienten geholfen werden…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- …
- 263
- › Next page